| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Viking Therapeutics, Inc.$38.86
-2.41 (-5.86%)
C 51Pipeline Score Overvalued Pharma · Commercial
Market Cap
3.59 B
EPS
-4.15
P/E Ratio
-
Value Trade
43.10 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
-
R&D Expenses
150.15 M
Operating CF
-113.98 M
Total Assets
608.24 M
Total Liabilities
106.33 M
Equity
501.92 M
D/E Ratio
12,345
-1.84 %
Week
-9.68 %
1 Month
0.65 %
3 Month
-9.23 %
6 Month
405.56 %
5 Year
263.41 %
All Time
Cash Data
Cash Position
602.96 M
Monthly Burn
37.99 M
Runway
13.8 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
2.16 M
52 Week Range
22.96 - 43.15
% held by Insiders
2.8 %
% held by Institutions
63.41 %
Enterprise Value
2.98 B
Total Shares
116.06 M
Short %
21.08 %
Float Shares
111.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Viking Therapeutics, Inc.
259Total events
1Upcoming
46Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 1
Event history 258
Q3 2026
Jun 24, 2026
Jun 24, 2026
▲Trial InitiationVK2735Trial
Initiation of Phase 3 VANQUISH-2 trial for subcutaneous VK2735
obesity/overweight with type 2 diabetessource ↗
Jun 11, 2026
May 12, 2026
◆Poster PresentationVK2735Presentation
Poster presentation of Phase 3 VANQUISH-1 trial design and enrollment demographics at ECO 2026
obesitysource ↗
Apr 29, 2026
Q2 2026
◆Full ResultsVK2735Clinical Data
Expect to report results from Phase 1 maintenance dosing study in mid-2026
obesitysource ↗
Mar 26, 2026
▲Enrollment CompleteVK2735Trial
Enrollment completed in Phase 3 VANQUISH-2 trial of subcutaneous VK2735 in adults with obesity and type 2 diabetes
obesity and type 2 diabetessource ↗
Mar 4, 2026
◆Oral PresentationPresentation
Viking Therapeutics to present at TD Cowen 46th Annual Health Care Conference
Feb 11, 2026
Drug Pipeline Intelligence
C51
Pipeline Score $2.0B
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.6x
rNPV / MCap Top 76%
Small Cap (rank 220 of 911)
Percentile RankViking Therapeutics, Inc. carries a moderate pipeline score (51/100), with $3.2B risk-adjusted pipeline value, led by VK2735 in Weight Loss (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VK2735 Small molecule | Weight Loss | Phase 3 | NCT07104500 | 50% | $1.7B | ACTIVE NOT_RECRUITING | 6,148 | VERY_FAST | B (70) | Aug 1, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VK2735 | obesity | Phase 2 | 2026-05-05 | In the 13-week Phase 2 VENTURE-Oral trial, treatment with oral VK2735 resulted in a significant weight loss of 21% compared to placebo, demonstrating its potential efficacy in obesity management. Read More | Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 Read More | |
VK2735 | obesity | Phase 2 | 2026-05-05 | In the 13-week Phase 2 VENTURE-Oral trial, treatment with oral VK2735 resulted in a significant weight loss of 21% compared to placebo, demonstrating its potential efficacy in obesity management. Read More | Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 Read More | |
VK2735 | obesity | Phase 2 | 2026-05-05 | In the 13-week Phase 2 VENTURE-Oral trial, treatment with oral VK2735 resulted in a significant weight loss of 21% compared to placebo, demonstrating its potential efficacy in obesity management. Read More | Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VKTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VKTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VKTX▲ +8.8%on this news
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Viking Therapeutics has initiated a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist aimed at weight loss. The trial will assess safety, tolerability, and pharmacokinetics in healthy adults. This development follows the FDA's clearance of VK3019's investigational new drug application. Viking aims to broaden treatment options for obesity management.
Read more →VKTXViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Viking Therapeutics has appointed Dr. Hubert C. Chen as Chief Medical Officer. Dr. Chen brings over 20 years of experience in drug discovery and clinical development, particularly in metabolic disorders. His leadership is expected to enhance Viking's clinical programs, especially as the company prepares for the commercialization of VK2735. This strategic move aims to strengthen the company's position in addressing obesity and related health challenges.
Read more →VKTXViking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences
Read more →VKTXViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Read more →VKTXTreatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding, VENTURE-Oral Study
The VENTURE-Oral study demonstrated that VK2735, an oral treatment, resulted in significant weight loss among participants. This randomized, placebo-controlled trial highlights the potential of VK2735 as an effective option for obesity management. The findings could have a substantial impact on future obesity treatments.
Read more →VKTXVANQUISH-1: Phase 3 Trial with Enrollment of a Diverse Population to Test Efficacy of Subcutaneous VK2735 in Adult Participants with Obesity or Overweight With Weight-Related Comorbidity
VKTX has initiated the VANQUISH-1 Phase 3 trial to evaluate the efficacy of VK2735 in adults with obesity or overweight conditions and related comorbidities. The trial aims to enroll a diverse population, enhancing the relevance of the findings. This represents a significant step in VKTX's efforts to address obesity-related health issues.
Read more →VKTXViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Viking Therapeutics announced two poster presentations at the European Congress on Obesity (ECO) 2026, showcasing data from its VK2735 program. The first poster presents findings from the 13-week Phase 2 VENTURE-Oral trial, highlighting efficacy and safety. The second poster discusses the ongoing Phase 3 VANQUISH-1 trial, which focuses on a diverse population of adults with obesity.
Read more →VKTXViking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQU
Viking Therapeutics reported its first quarter financial results for 2026, highlighting significant progress in its clinical pipeline, particularly with VK2735 for obesity treatment. The VANQUISH Phase 3 trials for VK2735 are fully enrolled, with both the subcutaneous and an upcoming oral formulation under development. The company's strong cash position and successful enrollment rates underscore investor and clinician enthusiasm for novel obesity treatment options. Additionally, Viking has filed an IND for VK3019, aiming for Phase 1 trial initiation in the second quarter of 2026.
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Viking Therapeutics, Inc. will release its financial results for Q1 2026 on April 29, 2026, followed by a conference call at 4:30 p.m. ET. The company is focused on developing innovative therapies for metabolic and endocrine disorders, with several clinical programs underway, including VK2735 and VK2809. The results will provide insights into the company's financial health and ongoing research efforts.
Read more →VKTXKatherine Mercier
Katherine Mercier has been appointed Vice President of Quality and Compliance at Viking Therapeutics. With over 20 years of experience in the pharmaceutical and biotechnology sectors, she has held significant leadership roles. Her expertise includes developing quality systems for late-stage clinical development and managing global contract manufacturing networks.
Read more →VKTXViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Viking Therapeutics has completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735, a dual agonist targeting obesity and type 2 diabetes. The trial involves around 1,000 adults and aims to evaluate the drug's efficacy and safety over 78 weeks. This milestone follows the earlier completion of the VANQUISH-1 study and reflects strong interest in new obesity treatments.
Read more →VKTXPrevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity
The article discusses the prevalence of cardiovascular, kidney, and metabolic conditions across different body mass index (BMI) categories, particularly focusing on severe obesity (Class III). It highlights the distinct health burdens associated with varying BMI levels. However, specific findings or data points from the study are not provided in the text.
Read more →VKTXWeekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
The article discusses the Phase 2 VENTURE study of VK2735, a dual agonist targeting GIP and GLP-1 receptors for weight management. The study is randomized and spans 13 weeks, focusing on the efficacy and safety of VK2735. Further details about the management and pipeline of the company are also provided.
Read more →VKTXBrandon D. Porter, Esq., M.B.A
Brandon D. Porter has been appointed as Vice President of Regulatory Affairs at Viking. With over 20 years of experience in the pharmaceutical and biotechnology sectors, he has a proven track record in regulatory strategy. Previously, he served as Executive Director at Protagonist Therapeutics and has held key roles at major companies like Pfizer and Janssen, where he contributed to multiple FDA drug approvals.
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Oral VK2735 to Advance into Phase 3 for Obesity in 3Q
Viking Therapeutics has reported its financial results for Q4 and FY 2025 while providing updates on its clinical programs. The company is advancing its oral formulation of VK2735 into Phase 3 trials in Q3 2026, while the ongoing VANQUISH trials for the subcutaneous formulation are nearing completion of enrollment. The company has also completed enrollment for its Phase 1 and Phase 2 studies, which have demonstrated statistically significant weight loss and safety. Viking has a strong cash position of $706 million to support these developments.
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Read more →VKTXKarthik Srinivasan, Ph.D.
Dr. Karthik Srinivasan leads Viking's Discovery and Preclinical Sciences group, bringing over 25 years of experience in the pharmaceutical and biotechnology sectors. His contributions include advancing therapies to IND and involvement in several marketed products. Previously, he held senior roles at Atomwise Inc., Turning Point Therapeutics, and Ferring Pharmaceuticals, and he is also a research advisor at the Broad Institute.
Read more →VKTXViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Read more →VKTXTavette Neskorik
Tavette Neskorik has been appointed as the Vice President of Clinical Operations at Viking. With over 25 years of experience in the pharmaceutical and biotechnology sectors, she has a proven track record in managing clinical trials from early to late-stage development. Her previous roles include significant positions at Mirati Therapeutics and Optimer Pharmaceuticals, where she oversaw pivotal trials leading to NDA submissions.
Read more →VKTXKaren Modesto, MD
Dr. Karen Modesto has been appointed as VP of Clinical Development at Viking. With over 25 years of experience in clinical research, she has worked at renowned institutions and has extensive expertise in overseeing clinical trials. Her primary research focus includes cardiovascular and metabolic disorders, enhancing Viking's capabilities in these areas.
Read more →VKTXKaren C. Chung, PharmD, MS
Karen C. Chung, PharmD, MS, has been appointed Vice President of Medical Affairs at Viking Therapeutics. With over 25 years of experience in the pharmaceutical and biotechnology sectors, she has held significant roles at GRAIL, Inc. and Juno Therapeutics. Dr. Chung's expertise spans product launches and lifecycle management across multiple therapeutic areas.
Read more →VKTXViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Read more →VKTXViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Read more →VKTX▼ -9.3%on this newsshared move
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Read more →VKTXMichael Morneau
Michael Morneau has been appointed as Vice President of Finance and Administration at Viking Therapeutics. With over 20 years of experience in the biotechnology and accounting sectors, he has held key financial roles at various companies, including Trius Therapeutics and Eli Lilly. Morneau holds an MBA and a Master of Arts in accounting, along with a BA in mathematics.
Read more →VKTXKenneth J. Herman
Kenneth J. Herman has been appointed as Senior Vice President of Commercial, Marketing and Sales at VKTX. With over 30 years of experience, he has a proven track record in leading the commercialization and lifecycle management of major pharmaceutical brands. His previous roles include senior positions at Orexigen Therapeutics and Arena Pharmaceuticals.
Read more →VKTXNils U. Olsson, Ph.D.
Nils U. Olsson, Ph.D., has been appointed as Senior Vice President of Technical Operations at Viking Therapeutics. With over 30 years of experience in Chemistry, Manufacturing and Control (CMC), Quality, and Regulatory Affairs, he has held significant positions in various biotech firms, including Cerus Corporation and Gilead Sciences. Dr. Olsson holds a Ph.D. in Analytical Chemistry from Stockholm University.
Read more →VKTXHubert C. Chen, M.D.
Dr. Hubert C. Chen is the Chief Medical Officer at Viking Therapeutics, bringing over 20 years of experience in advancing therapies from discovery to regulatory approval. He has held leadership positions at several biopharma companies and has a strong background in obesity and diabetes programs. Dr. Chen is well-educated, with degrees from Stanford and Columbia, and completed his residency at Massachusetts General Hospital.
Read more →VKTXNeil Aubuchon
Neil Aubuchon has been appointed as Chief Commercial Officer at Viking Therapeutics. He brings over 20 years of experience in the biopharmaceutical industry, having held leadership roles in commercial and marketing functions. His previous positions include CCO at AbCellera and global marketing lead at Amgen, where he focused on cardiometabolic therapies.
Read more →VKTXGeoffrey Barker, Ph.D.
Geoffrey Barker, Ph.D., has been appointed as Chief Development Officer at Viking Therapeutics. With 30 years of experience in pharmaceutical and nonclinical development, he previously held senior roles at various companies, including overseeing Phase 1 and Phase 2 candidates. Dr. Barker holds a Ph.D. in analytical chemistry from the State University of New York at Binghamton.
Read more →VKTXGreg Zante
Greg Zante has been appointed as the Chief Financial Officer of Viking Therapeutics. With over 25 years of experience in financial management within the biotechnology sector, he previously served as senior vice president of finance at Viking. Zante has held CFO roles at other biopharmaceutical companies and is a certified public accountant.
Read more →VKTXMarianne Mancini
Marianne Mancini is the Chief Operating Officer at Viking Therapeutics, bringing over 30 years of experience in the pharmaceutical and biotechnology sectors. She has a proven track record in clinical operations, having previously held senior positions at Ambit Biosciences and Aires Pharmaceuticals. Mancini's educational background includes a MA in Bioethics and an MBA.
Read more →VKTX▼ -6.1%on this newsshared move
Brian Lian, Ph.D.
Dr. Brian Lian is the President and CEO of Viking Therapeutics, bringing a wealth of experience in biotechnology. He has held significant roles in equity research and drug discovery, focusing on various therapeutic areas. His academic credentials include an MBA and a Ph.D. in organic chemistry, underscoring his expertise in the field.
Read more →VKTXViking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Read more →VKTXViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Read more →VKTXMatthew Singleton
Matthew Singleton has a rich background in finance and accounting, having served as CFO of CitationAir since 2000. His career includes significant roles at CIBC World Markets and Arthur Andersen, showcasing his expertise in financial reporting standards. Singleton also contributed to Cubist Pharmaceuticals as a director and Audit Committee Chair.
Read more →VKTXVANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
The article discusses the VANQUISH-2 trial, a Phase 3 study evaluating VK2735 for treating obesity in adults with Type 2 Diabetes. This trial is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy of weekly subcutaneous administration. The focus on this demographic addresses a critical health concern.
Read more →VKTXPrevalence of cardiometabolic conditions across body mass index categories—the distinct burden of severe (class III) obesity
The article discusses the prevalence of cardiometabolic conditions across various body mass index (BMI) categories, particularly focusing on the severe (class III) obesity group. It highlights the distinct burden faced by individuals with severe obesity in terms of health risks and associated conditions. The content appears to be part of a broader overview related to VKTX's management and pipeline.
Read more →VKTXCharles A. Rowland Jr.
Mr. Charles A. Rowland Jr. brings over 30 years of experience in the biopharmaceutical sector, having held key leadership roles in various companies. He was the CEO of Aurinia Pharmaceuticals and CFO of ViroPharma, where he helped the company achieve substantial growth. Rowland also serves on the boards of several biotechnology firms.
Read more →VKTXViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek 2025
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek 2025
Read more →VKTX▲ +5.3%on this newsshared move
Kathy Rouan, Ph.D.
Dr. Kathy Rouan brings nearly 30 years of experience in the pharmaceutical industry, most recently as senior vice president at GlaxoSmithKline. She has a strong background in clinical operations and project management, having led the approval of Arzerra for chronic lymphocytic leukemia. Dr. Rouan holds a Ph.D. in pharmaceutical sciences.
Read more →VKTXImpact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study
The article discusses the VENTURE study, which focuses on the effects of VK2735 on weight, prediabetes, and cardiometabolic status. The study aims to provide insights into VK2735's potential benefits in managing these health concerns. Further details on the study's methodology and results are not provided in the text.
Read more →VKTXVANQUISH-1 Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity
VKTX has announced the design of the VANQUISH-1 Phase 3 trial for VK2735, a subcutaneous treatment aimed at adults with overweight or obesity. This trial represents a critical step in evaluating the efficacy and safety of VK2735. The initiative reflects VKTX's commitment to addressing obesity, a prevalent health concern.
Read more →VKTX▼ -5.5%on this newsshared move
Matthew W. Foehr
Matthew W. Foehr has been the CEO of OmniAb, Inc. since November 2022, bringing over 25 years of pharmaceutical industry experience. His previous roles include COO at Ligand Pharmaceuticals and various leadership positions at GSK and Stiefel Laboratories. Foehr holds a Bachelor of Science in Biology and has authored numerous scientific publications.
Read more →VKTX▼ -5.5%on this newsshared move
Lawson Macartney, DVM, Ph.D.
Dr. Lawson Macartney has been the Chairperson of the Board since May 2015 and has a rich background in biopharmaceuticals. He previously served as CEO of Scout Bio and held leadership positions at Ambrx, Shire AG, and GSK. His academic credentials include a Ph.D. from Glasgow University and veterinary training.
Read more →VKTXViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025
Read more →VKTXViking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceedi
Viking Therapeutics reported its third quarter financial results and provided a corporate update, highlighting advancements in its clinical programs. The Phase 2 VENTURE-Oral Dosing study of VK2735 for obesity met its primary and secondary endpoints, showing significant weight loss. Concurrently, the Phase 3 VANQUISH trials are proceeding on schedule with strong patient enrollment. Their cash position stands at $715 million, ensuring robust support for ongoing development of VK2735 and additional programs.
Read more →VKTXViking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Read more →VKTX▲ +6.3%on this news
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
Read more →VKTX▼ -42.1%on this news
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Study Achieves Primary and Secondary Endpoints, Demonstrating Statistic
Viking Therapeutics announced positive results from its Phase 2 VENTURE-Oral Dosing trial for VK2735, targeting obesity. The study achieved significant weight loss in patients, with a mean reduction of up to 12.2% compared to placebo. VK2735 was found to be safe and well-tolerated, with most adverse events classified as mild or moderate. However, the treatment group observed a higher discontinuation rate due to adverse events compared to the placebo group.
Read more →VKTXViking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesit
Viking Therapeutics reported its financial results for Q2 2025, highlighting significant milestones in its clinical programs, particularly for VK2735 in obesity treatment. The company announced the start of Phase 3 VANQUISH trials and completion of enrollment in the Phase 2 VENTURE-Oral Dosing Trial. Additionally, Viking is poised to submit an IND application for its amylin agonist program later this year, supported by a strong cash position. The upcoming months are critical as top-line results from ongoing trials are anticipated to provide further insights into VK2735's efficacy.
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
Read more →VKTXViking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Read more →VKTXObesity Impact on Incidence of Chronic Comorbid Conditions
The article provides an overview of VKTX's management, board of directors, and pipeline products, including VK2735, VK3019, VK2809, VK0214, and VK5211. It also includes information on investor relations, stock information, and corporate governance. However, it lacks specific details about the impact of obesity on chronic comorbid conditions.
Read more →VKTXViking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25  
Viking Therapeutics reported strong financial results for Q1 2025, revealing a cash position of $852 million. The company is set to initiate Phase 3 trials for VK2735, a treatment for obesity, in Q2 2025, following the successful enrollment of its Phase 2 VENTURE trial. Additionally, Viking has secured a manufacturing agreement with CordenPharma, ensuring support for future commercialization of VK2735. Results from the VENTURE trial are anticipated in the second half of 2025.
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Read more →VKTX▼ -5.9%on this news
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Read more →VKTX▼ -5.2%on this news
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical
Viking Therapeutics has signed a multi-year manufacturing agreement with CordenPharma, aimed at supporting the commercialization of its dual agonist product, VK2735. The deal secures dedicated supply capacity for both the active pharmaceutical ingredient and finished products, including autoinjectors, vials, and oral tablets. Viking anticipates the agreement could foster significant commercial demand, given the projected multi-billion-dollar opportunity. Additionally, Viking will make prepayments totaling $150 million spread over the next few years, covering manufacturing costs for the injectable and oral forms of VK2735.
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Initiation of Phase 3 Studies for Subcutaneous VK2735
Viking Therapeutics announced its financial results for the fourth quarter and year-end 2024, reporting a cash position of $903 million. The company highlighted the successful outcomes of several clinical trials, including the positive results from the Phase 2 VENTURE study for VK2735, which demonstrated significant weight loss in patients. Viking is preparing to initiate Phase 3 studies for VK2735 in obesity by the second quarter of 2025, while also advancing an oral formulation and exploring new pipeline options. The company remains focused on developing novel therapies for metabolic disorders.
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Read more →VKTXViking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Read more →VKTXViking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Read more →VKTXViking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
Read more →VKTXViking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
Read more →VKTX▼ -13.4%on this news
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek 2024 Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolera
Viking Therapeutics announced new data regarding its VK2735 obesity treatment at ObesityWeek 2024. Clinical trial results indicated up to 6.8% placebo-adjusted mean weight loss after 28 days of treatment, with 100% of subjects achieving at least 5% weight loss. The treatment demonstrated a positive safety profile with primarily mild adverse events. Results from an additional Phase 2 study also indicated significant weight loss efficacy over a 13-week period, showing the potential for VK2735 in treating obesity.
Read more →VKTX▼ -13.4%on this newsshared move
First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults
VKTX is initiating a first-in-human study for VK2735, an oral GLP-1/GIP co-agonist. This study aims to evaluate the safety and efficacy of VK2735 in healthy adults. The development of VK2735 could provide a novel treatment option in the biopharma landscape.
Read more →VKTXResults From the 13-Week VENTURE Phase 2a Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Patients
The article discusses the 13-week VENTURE Phase 2a study of VK2735, a GLP-1/GIP co-agonist, aimed at treating obesity in patients. The study's results are yet to be detailed, indicating a focus on the drug's potential efficacy and safety. Further insights into the study's outcomes may be anticipated in future communications.
Read more →VKTXViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2024
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2024
Read more →VKTXViking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned
Viking Therapeutics reported its Q3 2024 financial results, highlighting promising advancements in its clinical pipeline. The company has planned an End-of-Phase 2 meeting for VK2735, a dual agonist for obesity, and is set to initiate a Phase 2 trial of an oral formulation of VK2735 later this year. Additionally, positive results from the Phase 2b VOYAGE trial of VK2809 in NASH/MASH will be presented at a forthcoming conference. With a robust cash position, Viking is well-positioned for further clinical milestones.
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
Read more →VKTX▼ -6.1%on this news
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Read more →VKTXViking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
Read more →VKTXViking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting P
Viking Therapeutics reported its second-quarter 2024 financial results, highlighting significant progress in its clinical pipeline. Notably, the company plans to advance VK2735 into Phase 3 trials for obesity, following positive Phase 2 trial results, which indicated up to a 15% reduction in body weight in participants. The company also announced plans for an end-of-Phase 2 meeting with the FDA for VK2809 in NASH/MASH while reporting promising results from other studies. Viking concluded the quarter with a solid financial position, ending with $942 million in cash to support its ongoing development efforts.
Read more →VKTX▼ -12.6%on this news
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
Read more →VKTXViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
Read more →VKTX▼ -9.7%on this news
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTX▼ -9.7%on this news
Tim Brons (Media) 415-675-7402 tbrons@vidasp.com
Viking Therapeutics has announced promising 52-week histologic data from its Phase 2b VOYAGE study of VK2809, focusing on patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The study showed that up to 75% of patients treated with VK2809 achieved NASH resolution without worsening fibrosis. Additionally, measures indicated significant improvements in fibrosis and reductions in liver fat content compared to placebo. The safety profile of VK2809 remained favorable, with low rates of reported adverse events.
Read more →VKTXViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in O
Viking Therapeutics announced its financial results for Q1 2024 alongside updates on its clinical trials. The Phase 2 VENTURE trial of VK2735 in obesity showed significant weight loss results, achieving primary endpoints safely. Additionally, the company reported promising data from a Phase 1 trial of oral VK2735. Viking raised $630 million through a public offering to support further development of its pipeline programs.
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Read more →VKTX▲ +16.8%on this news
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 D
Viking Therapeutics announced positive results from a Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, showcasing encouraging weight loss outcomes. The study reported a maximum placebo-adjusted weight loss of 3.3% over 28 days, with 57% of participants achieving over 5% weight loss. The safety profile appeared favorable, with minimal gastrointestinal side effects reported. Following these results, Viking Therapeutics is planning a Phase 2 trial in obesity for later this year.
Read more →VKTX▲ +7.2%on this news
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, CA –
Viking Therapeutics, Inc. announced the successful closing of a public offering, raising about $632.5 million from the sale of 7,441,650 shares at $85.00 each. This offering also included the full exercise of an underwriters' option for additional shares. The gross proceeds will be used to further develop their compounds VK2809, VK2735, and VK0214, which are focused on treating metabolic and endocrine disorders. The offering was facilitated by several financial institutions, ensuring a robust support structure for Viking's ongoing developmental efforts.
Read more →VKTX▲ +11.1%on this newsshared move
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock SAN DIEGO, CA –
Viking Therapeutics has priced its public offering of 6,471,000 shares of common stock at $85.00 per share, raising approximately $550 million. The offering aims to finance the continued development of its drug programs VK2809, VK2735, and VK0214. The offering is expected to close around March 4, 2024, pending customary conditions. Viking is leveraging these funds to advance its therapies focused on metabolic and endocrine disorders.
Read more →VKTX▲ +121%on this news· ran to +146% by day 1shared move
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Read more →VKTX▲ +121%on this news· ran to +146% by day 1shared move
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity Study Achieves Primary and all Secondary Endpoints, Demonstrating Stat
Viking Therapeutics reported positive top-line results from its Phase 2 VENTURE trial for VK2735, a dual GLP-1/GIP receptor agonist aimed at treating obesity. The trial achieved its primary and all secondary endpoints, with participants experiencing significant weight loss compared to placebo. VK2735 was well-tolerated, with most treatment-emergent adverse events categorized as mild or moderate. Following these promising results, Viking plans to engage with the FDA for further development steps.
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonis
Viking Therapeutics has reported its fourth-quarter and year-end 2023 financial results, highlighting significant progress across multiple clinical programs. Key upcoming milestones include expected results from the Phase 2 VENTURE trial of VK2735 in obesity and the Phase 2b VOYAGE study for VK2809 in treating non-alcoholic steatohepatitis. The company ended the year with a robust cash position, indicating readiness to advance its initiatives. Viking anticipates an exciting year ahead as it continues to develop its clinical pipeline.
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
Read more →VKTXViking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2023
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2023
Read more →VKTXViking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully
Viking Therapeutics announced its financial results for Q3 2023 and provided an update on its clinical programs. The Phase 2 VENTURE trial for VK2735, a GLP-1/GIP agonist targeting obesity, has been fully enrolled and is set to report results in the first half of 2024. The company also continues to enroll patients in a Phase 1 trial of an oral formulation of VK2735 and advancing the VOYAGE study for VK2809 in NASH and fibrosis, with results expected in the same timeframe. Viking maintains a robust cash position of $376 million to support its operations and pipeline advancements.
Read more →VKTXViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
Read more →VKTXViking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Read more →VKTXViking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Read more →VKTXViking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Read more →VKTXViking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Reported Positive Top-Line Results from Phase 2b VOYAGE Study of V
Viking Therapeutics reported strong financial results for Q2 2023 and provided updates on their clinical pipeline. Notable highlights include positive Phase 2b results from the VOYAGE study of VK2809 in NASH patients, showing significant liver fat reduction. The company is also moving forward with plans for a Phase 2 study of VK2735 in obesity, with results anticipated in the near term. The financial position remains robust, with $393 million in cash available to support further developments.
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
Read more →VKTX▲ +12.1%on this news
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTXViking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Three Additional Data Announcements Expected in 2023 • Compl
Viking Therapeutics reported its financial results for Q1 2023 and provided an update on its clinical pipeline. The company has completed enrollment in the Phase 2b VOYAGE study for VK2809, with data anticipated in the second quarter. Promising results from Phase 1 trials of VK2735 have shown significant weight loss and good safety profiles. Additionally, Viking successfully completed a public offering, raising substantial funds to support its clinical activities throughout the year.
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
Read more →VKTXViking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
Read more →VKTX▲ +5.5%on this news
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, CA –
Viking Therapeutics announced the successful closing of a public offering of 19,828,300 shares of common stock at $14.50 per share, raising around $287.5 million. The offering included the complete exercise of an underwriters' option to purchase additional shares. The proceeds from the offering will primarily fund the continued development of the company's VK2809, VK2735, and VK0214 programs, which target various metabolic and endocrine disorders. The offering was managed by William Blair & Company and Raymond James & Associates, among others.
Read more →VKTXViking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock SAN DIEGO, CA –
Viking Therapeutics, Inc. has announced the pricing of its underwritten public offering, selling 17,242,000 shares of common stock at $14.50 per share, aiming to raise approximately $250 million. The company plans to use the proceeds for the continued development of its VK2809, VK2735, and VK0214 programs, as well as for general corporate purposes. The offering is expected to close on or about April 3, 2023, pending customary closing conditions. This capital infusion is intended to bolster Viking's research initiatives in metabolic and endocrine disorders.
Read more →VKTX▲ +69.3%on this news· ran to +83% by day 3shared move
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 Expands Potential Opportunities for VK2735 with Highly Differentiated Dosing Option Data An
Viking Therapeutics has initiated a Phase 1 clinical trial to evaluate an oral formulation of VK2735, a dual GLP-1 and GIP receptor agonist. This study follows positive results from a previous trial of a subcutaneous version of the drug. The oral formulation aims to expand treatment possibilities and is expected to report results in the second half of 2023. Viking's ongoing commitment to developing innovative therapies indicates confidence in the drug's potential for treating metabolic disorders.
Read more →VKTX▲ +69.3%on this news· ran to +83% by day 3shared move
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 Up to 6.0% Placebo-Adjusted Mean Weight Loss (7.8% From Baseline) Observed After 28 Days VK2735 Shown to be Safe
Viking Therapeutics recently announced positive results from its Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist. The trial demonstrated a placebo-adjusted mean weight loss of up to 6.0% over 28 days and showed VK2735 to be safe and well-tolerated. The company is planning to initiate a Phase 2 trial focused on obesity treatment in mid-2023, building on the encouraging safety and pharmacokinetic data obtained. The results suggest that higher doses may be achievable, warranting further investigation.
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Data from Three Clinical Programs Expected in 2023 Enrollment
Viking Therapeutics reported its financial results for Q4 2022, highlighting a net loss of $19.6 million. The CEO expressed optimism for 2023, expecting data from three clinical programs. The company's lead compound, VK2809, completed enrollment in its Phase 2b VOYAGE trial, with data expected soon. Other compounds, VK2735 and VK0214, are also progressing in clinical trials demonstrating promising results in earlier studies.
Read more →VKTXViking Therapeutics to Present at SVB Securities Global Biopharma Conference
Viking Therapeutics to Present at SVB Securities Global Biopharma Conference
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
Read more →VKTXViking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTXViking Therapeutics to Present at Stifel 2022 Healthcare Conference
Viking Therapeutics to Present at Stifel 2022 Healthcare Conference
Read more →VKTXViking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Company Positioned to Announce Data from Three Clinical Programs in 2023 VK2
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, October 26, 2022 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced it
Read more →VKTX▼ -12.1%on this news
Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
Read more →VKTX▲ +8.4%on this news· ran to +20% by day 3
Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Read more →VKTXViking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Clinical Data From Three Programs Anticipated in Next Twelve Months VK2809
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, July 27, 2022 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its f
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
Read more →VKTXViking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Read more →VKTXViking Therapeutics to Present at William Blair Biotech Focus Conference 2022
Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
Read more →VKTXViking Therapeutics to Present at H.C. Wainwright Global Investment Conference
Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference
Read more →VKTXViking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confir
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 27, 2022 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fi
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022
Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022
Read more →VKTXViking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Read more →VKTXViking Therapeutics to Present at Upcoming Investor Conferences
Viking Therapeutics to Present at Upcoming Investor Conferences
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Data From Three Clinical Programs Expected in the Next 12-18 M
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, February 9, 2022 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTXViking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference
Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference
Read more →VKTX▼ -6.8%on this newsshared move
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022
Read more →VKTX▼ -6.6%on this news
Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
Read more →VKTXViking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
Read more →VKTX▲ +6.1%on this news
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Read more →VKTXViking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
Read more →VKTXViking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Proceeding
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, November 3, 2021 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTX▲ +5.5%on this newsshared move
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021
Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021
Read more →VKTXViking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Read more →VKTXViking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
Read more →VKTXViking Therapeutics to Participate in Upcoming Investor Conferences
Viking Therapeutics to Participate in Upcoming Investor Conferences
Read more →VKTXViking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Enrollment Continues in Phase 2b VOYAGE Study Evaluating VK2809 for the Tre
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, July 28, 2021 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fin
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021
Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021
Read more →VKTXViking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Read more →VKTXViking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
Read more →VKTXViking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today U.S. and European Sites Continue to Enroll Phase 2b VOYAGE Study Evaluating
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 28, 2021 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fi
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
Read more →VKTXViking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of N
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, February 17, 2021 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
Read more →VKTXViking Therapeutics Announces Senior Management Team Appointments
Viking Therapeutics Announces Senior Management Team Appointments
Read more →VKTXViking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
Read more →VKTXViking Therapeutics to Present at Stifel Healthcare Conference 2020
Viking Therapeutics to Present at Stifel Healthcare Conference 2020
Read more →VKTXViking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH O
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, October 28, 2020 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
Read more →VKTXViking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
Read more →VKTXViking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
Read more →VKTXViking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
Read more →VKTXViking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; N
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, July 29, 2020 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fin
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020
Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020
Read more →VKTXViking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
Read more →VKTXViking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH &#x
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 30, 2020 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fi
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
Read more →VKTXViking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
Read more →VKTXViking Therapeutics to Present at Biotech Showcase 2020
Viking Therapeutics to Present at Biotech Showcase 2020
Read more →VKTXViking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTXViking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 8:30 a.m. ET today • IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confir
Conference call scheduled for 8:30 a.m. ET today SAN DIEGO, November 5, 2019 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced it
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
Read more →VKTXViking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Read more →VKTXViking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, August 1, 2019 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Read more →VKTXViking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors SAN DIEGO, CA - July 2, 2019 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorde
Read more →VKTXViking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Resul
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, May 2, 2019 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its finan
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Read more →VKTXViking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019
Read more →VKTXViking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress 2019
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Additional VK2809 Phase 2 Data to be Presented at EAS
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, March 13, 2019 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fi
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
Read more →VKTXViking Therapeutics to Participate in Upcoming Investor Conferences and Events
Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
Read more →VKTXViking Therapeutics to Present at Biotech Showcase 2019
Viking Therapeutics to Present at Biotech Showcase 2019
Read more →VKTXViking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting 2018
Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting 2018
Read more →VKTXViking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Announced Positive Top-Line Results from Phase 2 Study of VK2809 in
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, November 7, 2018 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018
Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018
Read more →VKTXViking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)
Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)
Read more →VKTXViking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting 2018
Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting 2018
Read more →VKTXViking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Read more →VKTXViking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock SAN DIEGO, CA - September 20, 2018 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metaboli
Read more →VKTXViking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol Study Achieves Primary Endpoint, Demonstrating
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients R
Read more →VKTXViking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment complete for VK2809 Phase 2 fatty liver and hypercholes
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, August 9, 2018 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fi
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018
Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018
Read more →VKTXViking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Read more →VKTXViking Therapeutics Announces Closing of Public Offering of Common Stock
Viking Therapeutics Announces Closing of Public Offering of Common Stock SAN DIEGO, CA - June 12, 2018 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine diso
Read more →VKTXViking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock
Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock SAN DIEGO, CA - June 7, 2018 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and e
Read more →VKTXViking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Read more →VKTXViking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK2809 Phase 2 fatty liver and hypercholesterolemia study enrolling
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, May 9, 2018 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its finan
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK5211 Phase 2 trial in hip fracture achieves primary
Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, March 7, 2018 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its fin
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
Read more →VKTXViking Therapeutics to Present at 2018 BIO CEO Investor Conference
Viking Therapeutics to Present at 2018 BIO CEO Investor Conference
Read more →VKTXViking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock SAN DIEGO, CA - February 2, 2018 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a
Read more →VKTXViking Therapeutics to Present at Biotech Showcase 2018
Viking Therapeutics to Present at Biotech Showcase 2018
Read more →VKTXViking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock SAN DIEGO, CA - December 6, 2017 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a
Read more →VKTXViking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose Dependent Incre
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following
Read more →VKTXViking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study nearing completion, data expected 4Q17 • VK2809 Phase 2 fatty liver and hyp
SAN DIEGO, November 8, 2017 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended Sept
Read more →VKTXViking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
Read more →VKTXViking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Read more →VKTXViking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
Read more →VKTXViking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Read more →VKTXViking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital SAN DIEGO, CA - September 29, 2017 - Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies f
Read more →VKTXViking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Read more →VKTXViking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTXViking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
Read more →VKTXViking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
Read more →VKTXViking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study fully enrolled, data expected 4Q17 • VK2809 Phase 2 fatty liver and hyperc
SAN DIEGO, August 9, 2017 -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June
Read more →VKTXViking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
Read more →VKTXViking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Read more →VKTXViking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors SAN DIEGO, CA - July 6, 2017 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine diso
Read more →VKTXViking Therapeutics Announces $4.3 Million Registered Direct Offering
Viking Therapeutics Announces $4.3 Million Registered Direct Offering SAN DIEGO, CA - June 14, 2017 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorde
Read more →VKTXViking Therapeutics Announces Promising Top-Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Promising Top-Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
Read more →VKTXViking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study enrollment nearing completion • VK2809 Phase 2 fatty liver and hypercholest
SAN DIEGO, May 10, 2017 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March
Read more →VKTXViking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
Read more →VKTXViking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update • VK5211 Phase 2 study in hip fracture proceeding, with results expected mid-year • VK2809 Phase
SAN DIEGO, March 21, 2017 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year
Read more →VKTXViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017
Read more →VKTXViking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Read more →VKTXViking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
Read more →VKTXViking Therapeutics to Present at 2017 BIO CEO Investor Conference
Viking Therapeutics to Present at 2017 BIO CEO Investor Conference
Read more →VKTXViking Therapeutics Announces Senior-Level Appointments to Management Team
Viking Therapeutics Announces Senior-Level Appointments to Management Team
Read more →VKTXViking Therapeutics to Present at Biotech Showcase 2017
Viking Therapeutics to Present at Biotech Showcase 2017
Read more →VKTXViking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
Read more →VKTXViking Therapeutics to Present at the LD Micro Main Event
Viking Therapeutics to Present at the LD Micro Main Event
Read more →VKTXViking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016
Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016
Read more →VKTXViking Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Conference Call and Webcast Today at 4:30 p.m. Eastern • VK5211 Phase 2 study in hip fracture proceeding in the U.S. a
Conference Call and Webcast Today at 4:30 p.m. Eastern SAN DIEGO, November 10, 2016 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today annou
Read more →VKTXViking Therapeutics to Host Conference Call to Discuss Third Quarter 2016 Financial Results
Viking Therapeutics to Host Conference Call to Discuss Third Quarter 2016 Financial Results
Read more →VKTXViking Therapeutics to Present at the 2016 BIO Investor Forum
Viking Therapeutics to Present at the 2016 BIO Investor Forum
Read more →VKTXViking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Novel Oral Thyroid Receptor Agonist has Unique Potential to Simultan
Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Novel Oral Thyroid Receptor Agonist has Unique Potential to Simultaneously Improve Plasma Lipid Profile and Reduce Hepatic Stea
Read more →VKTXViking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of the American Thyroid Association
Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of the American Thyroid Association
Read more →VKTXViking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
Read more →VKTXViking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital
Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital SAN DIEGO, CA - August 25, 2016 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for m
Read more →VKTXViking Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update VK5211 Phase 2 study in hip fracture proceeding in U.S., expanding in EU VK2809 Phase 2 study in hypercholesterolemia and fa
SAN DIEGO, August 10, 2016 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter of 2016,
Read more →VKTXViking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
Read more →VKTXViking Therapeutics to Present at the 2016 Marcum Microcap Conference
Viking Therapeutics to Present at the 2016 Marcum Microcap Conference
Read more →VKTXViking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update - VK5211 Phase 2 study for hip fracture ongoing - Positive Phase 1b data on VK2809 presented at American College of Cardiolog
SAN DIEGO, May 10, 2016 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for t
Read more →VKTXViking Therapeutics Announces Full Exercise of Over-Allotment Option
Viking Therapeutics Announces Full Exercise of Over-Allotment Option SAN DIEGO, CA - May 2, 2016 - Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic an
Read more →VKTXViking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants
Viking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants SAN DIEGO, CA - April 13, 2016 - Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therap
Read more →VKTXViking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects
Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects
Read more →VKTXViking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants SAN DIEGO, CA - April 8, 2016 - Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapi
Read more →VKTXViking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update Key Advancements in Three Lead Programs: VK5211, VK2809 and VK0214 Phase 2 Study of VK2809 in Hypercholesterole
Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update SAN DIEGO, CA - March 8, 2016 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first
Read more →VKTXForward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Sec
Corporate Presentation Biotech Showcase, January 2016 EXHIBIT 99.1 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Pri
Read more →VKTXViking Therapeutics to Present at Biotech Showcase 2016
Viking Therapeutics to Present at Biotech Showcase 2016
Read more →VKTXViking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment
Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment
Read more →VKTXViking Therapeutics and Kennedy Krieger Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agonists for X-Linked Adrenoleukodystrophy (X-ALD)
Viking Therapeutics and Kennedy Krieger Institute Sign Collaboration Agreement to Evaluate Novel Thyroid Beta Agonists for X-Linked Adrenoleukodystrophy (X-ALD)
Read more →VKTXViking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease
Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease
Read more →VKTXViking Therapeutics to Present at Upcoming Life Science Industry Events
Viking Therapeutics to Present at Upcoming Life Science Industry Events
Read more →VKTXViking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update Commenced Dosing in Phase 2 Study of VK5211 in Acute Hip Fracture Phase 2 Study of VK2809 in Hypercholesterolemia and Fatty L
Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update SAN DIEGO, CA - November 5, 2015 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class o
Read more →VKTXViking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture Oral Small Molecule SARM Designed to Stimulate Muscle and Bone Formation Post-Surgery
Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture Oral Small Molecule SARM Designed to Stimulate Muscle and Bone Formation Post-Surgery SAN DIEGO, CA November 3, 2015 Viking Therapeutics, Inc. ( Viking ) (NASDAQ: VKTX), a clinical-st
Read more →VKTXViking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator (SARM), in Healthy Elderly Subjects Positive Results Pave Way for Advancing VK5211 into Phas
Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator (SARM), in Healthy Elderly Subjects Positive Results Pave Way for Advancing VK5211 into Phase 2 Trial in Hip Fracture Patients SAN DIEGO, CA October
Read more →VKTXViking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator (SARM), for Acute Hip Fracture
Viking Therapeutics has initiated a clinical trial for VK5211, a selective androgen receptor modulator, aimed at aiding recovery in patients post-hip fracture surgery. The first subjects have been dosed in a safety study, leading to a Phase 2 trial to assess efficacy in increasing lean body mass. The company anticipates dosing the first patient in this efficacy study by Q4 2015.
Read more →VKTXViking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Viking Therapeutics reported its second quarter 2015 financial results, highlighting significant progress in its clinical pipeline. The company has initiated Phase 2 trials for VK5211 and VK2809, targeting hip fractures and fatty liver disease, respectively. Additionally, Viking successfully completed a $22.3 million IPO to support its development efforts. Despite a net loss of $7.9 million, the company remains optimistic about its future prospects.
Read more →VKTXViking Therapeutics to Conduct Phase 2 Trial of VK2809 in Patients With Cholesterolemia and Fatty Liver Disease
Viking Therapeutics plans to initiate a Phase 2 trial for VK2809, targeting patients with hypercholesterolemia and fatty liver disease. The trial aims to assess the drug's efficacy and safety in approximately 100 patients. VK2809 has shown promising results in earlier studies, indicating significant reductions in LDL cholesterol and liver fat. The company expects to file an IND application and start the trial in late 2015.
Read more →VKTXViking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM) in Acute Hip Fracture
Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM) in Acute Hip Fracture
Read more →VKTXViking Therapeutics, Inc. Announces Chairman Appointment
Viking Therapeutics, Inc. Announces Chairman Appointment SAN DIEGO, CA June 4, 2015 Viking Therapeutics, Inc. ( Viking ) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and e
Read more →VKTXViking Therapeutics, Inc. Announces Full Exercise of Over-Allotment Option
Viking Therapeutics, Inc. Announces Full Exercise of Over-Allotment Option SAN DIEGO, CA May 29, 2015 Viking Therapeutics, Inc. ( Viking ) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies f
Read more →VKTXViking Signs Broad Licensing Deal with Ligand Pharmaceuticals for Rights to Five Novel Therapeutic Programs
Viking Signs Broad Licensing Deal with Ligand Pharmaceuticals for Rights to Five Novel Therapeutic Programs
Read more →VKTXViking Therapeutics, Inc. Announces Closing of Initial Public Offering
Viking Therapeutics, Inc. Announces Closing of Initial Public Offering
Read more →VKTXViking Therapeutics, Inc. Announces Pricing of Initial Public Offering
Viking Therapeutics, Inc. Announces Pricing of Initial Public Offering
Read more →VKTXViking Therapeutics Announces Research Collaboration for Novel Thyroid Beta Agonists as Potential Treatment for X-Linked Adrenoleukodystrophy
Viking Therapeutics Announces Research Collaboration for Novel Thyroid Beta Agonists as Potential Treatment for X-Linked Adrenoleukodystrophy
Read more →VKTXViking Systems' 3DHD Receives Enthusiastic Response at The 12th World Congress of Endoscopic Surgery
WESTBOROUGH, Mass., April 20, 2010 (GLOBE NEWSWIRE) -- Viking Systems (OTCBB:VKNG) announced today that preclinical surgical video created using a Viking Systems' "Next Generation" 3DHD prototype visualization system displayed on a Sony prototype medical grade 3DHD monitor was en
Read more →VKTXViking Systems, Inc. Gains Clearance to Market 3-D Visualization Systems in Australia and New Zealand
SAN DIEGO, Jan. 4, 2007 (PRIME NEWSWIRE) -- Viking Systems, Inc. (OTCBB:VKSY), a designer, manufacturer and marketer of high-performance laparoscopic vision systems for use in minimally invasive surgical (MIS) procedures, has partnered with Device Technologies, a private Australi
Read more →Competitive Position
How VKTX ranks across every disease it competes inCompetitive Position is a premium feature
See how VKTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial